JULY 11, 2024 by Robin Foster Three of four patients stop taking Ozempic or Wegovy two years after being prescribed the blockbuster drugs for weight loss, a new analysis shows. Conducted by Prime Therapeutics and Magellan Rx Management (MRx), the review sifted through pharmacy and medical claims data for 3,364 people with insurance plans that...
by Cynthia McCormick Hibbert, Northeastern University Credit: Unsplash/CC0 Public Domain With Ozempic-type weight loss drugs in short supply, more people are turning to old-school weight loss drugs such as Qsymia and Contrave, which come in pill form but also include serious warning labels. Savanna DiCristina, a Northeastern assistant clinical professor of pharmacy and health systems...
NEWS RELEASE 3-JUL-2024 A new Mass Eye and Ear-led study is the first to discover that people prescribed semaglutide, sold as Ozempic and Wegovy, have a higher risk of developing a form of blindness due to optic nerve disease known as non-arteritic anterior ischemic optic neurop Peer-Reviewed PublicationMASS EYE AND EAR A new study led...
by Cleveland Clinic Credit: Unsplash/CC0 Public Domain A Cleveland Clinic study shows that bariatric surgery performed in patients with obesity and moderate to severe obstructive sleep apnea is associated with a significantly lower risk of death and major adverse cardiovascular events, compared with patients who did not have the surgery. This study was published in...
Mounjaro and Zepbound can help qualified individuals lose and maintain weight and blood glucose levels. These medicines are not recommended for short-term use. Stopping them can prompt weight regain, blood sugar spikes, and increased appetite, among other side effects. Like Ozempic and Wegovy, Mounjaro and Zepbound can help people control blood sugar levels and reduce...
Medscape Medical News > Features Marilynn Larkin June 05, 2024 Now that semaglutide (Wegovy), tirzepatide (Zepbound), and other injectables have created an insatiable market for weight loss drugs, biotech and pharmaceutical companies are roaring ahead with oral formulations, which promise a greater level of convenience, in line with patient preference. One particularly intriguing entry is...
Medscape Medical News > Conference News > DDW 2024 Damian McNamara, MA May 23, 2024 WASHINGTON, DC — In contrast with a previous study that found glucagon-like peptide 1 (GLP-1) receptor agonists associated with an increased risk for acute pancreatitis and bowel obstruction, a new retrospective study found no significant link to these complications. The...
Medscape Medical News > Conference News > DDW 2024 Damian McNamara, MA May 09, 2024 Updated May 13, 2024 // Editor’s note: The story has been updated with additional comments from Dr Loren Laine of Yale School of Medicine. Ablation of the gastric fundus to reduce production of the “hunger hormone” ghrelin resulted in decreased...
By Bronwyn Thompson The 2.0 weight-loss drugs will target the brain’s plasticity Depositphotos The current breakthrough weight-loss drugs are only the beginning, according to Danish researchers hard at work on a new treatment that targets the brain’s natural plasticity, which could offset bad side effects and provide more long-term benefits. “I consider the drugs available...
By Brenda Goodman, CNN Published 12:01 AM EDT, Mon May 20, 2024 GLP-1 medications curb hunger by slowing passage of food through the stomach. Jaap Arriens/NurPhoto/Getty Images CNN — Injected medications that treat diabetes and obesity increase the risk of a rare but serious side effect: stomach paralysis, according to new data on the real-world...
